Natera, Inc.
A clinical genetics company that reads traces of DNA floating in the blood to detect cancer, screen pregnancies, and monitor transplanted organs — its best-known tests include Signatera for cancer recurrence, Panorama for prenatal screening, and Prospera for transplant rejection. It began in 2004 as Gene Security Network, born from a founder's personal loss when a relative's baby died days after birth with an undetected condition. The company later renamed itself Natera, a word meant to echo "birth," "nature," and "earth."
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 13G/APassive | 6.3% | 9.02M | Aug 14, 2026 |
| Vanguard Capital Management | 13GPassive | 5.08% | 7.21M | Apr 30, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| JPMORGAN CHASE & CO. | 13G/APassive | 9.1% | 12.83M | Jan 23, 2026 |
| BlackRock, Inc. | 13G/APassive | 5.6% | 7.57M | Apr 17, 2025 |